Influenza virus infection
Conditions
Interventions
None listed
Sponsors
Department of Clinical Infectious Diseases, Aichi Medical University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients or guardian of the patients with informed consent. 2) Age: more than 16 years ( at the time the informed consent form is signed ) 3) Gender: Male or female 4) Patients with influenza A and/or B diagnosed with a nasal or throat swab specimen by RAT ( rapid antigen test ) etc. 5) Patients of the following any criteria( at the time the informed consent form is signed ): Inhaling of oxygen, Progressing diabetes, Renal insufficiency, Treating in ICU
Exclusion criteria
Exclusion criteria: 1) Patients with convulsions or other neurological symptoms ( consciousness disorder, abnormal behavior/speech ) within the past 2 years. 2) History of hypersensitivity, allergy or serious adverse drug event caused by oseltamivir phosphate ( Tamiflu ), zanamivir hydrate ( Relenza ) or peramivir hydrate ( Rapiacta ). 3) Women who are pregnant or suspected to be pregnant and women who are breast-feeding. 4) Any other patients whose condition is inappropriate for the evaluation of this clinical study as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The improvement in clinical status ( improvement ratio ) | — |
Secondary
| Measure | Time frame |
|---|---|
| The time to alleviation of influenza symptoms. Incidence of influenza-related complications. | — |
Countries
Japan
Outcome results
None listed